BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 32720828)

  • 1. Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center phase I/II experience.
    Sawas A; Ma H; Kuruvilla J; Lue JK; Deng C; Marchi E; Montanari F; Cheng B; Savage KJ; Villa D; Crump M; Connors JM; O'Connor OA
    Leuk Lymphoma; 2020 Dec; 61(12):3014-3017. PubMed ID: 32720828
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patients.
    Zinzani PL; Vitolo U; Viviani S; Corradini P; Motta G; Tani M; Cascavilla N; Hohaus S; Merli F; Argnani L; Broccoli A
    Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):404-8. PubMed ID: 25840816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma.
    Vinti L; Pagliara D; Buffardi S; Di Ruscio V; Stocchi F; Mariggiò E; Parasole R; Di Matteo A; Petruzziello F; Paganelli V; De Vito R; Del Bufalo F; Strocchio L; Locatelli F
    Pediatr Blood Cancer; 2022 Apr; 69(4):e29557. PubMed ID: 35107876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients.
    Uncu Ulu B; Dal MS; Yönal Hindilerden İ; Akay OM; Mehtap Ö; Büyükkurt N; Hindilerden F; Güneş AK; Yiğenoğlu TN; Başcı S; Kızıl Çakar M; Yanardağ Açık D; Korkmaz S; Ulaş T; Özet G; Ferhanoğlu B; Nalçacı M; Altuntaş F
    J Chemother; 2022 May; 34(3):190-198. PubMed ID: 34514960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brentuximab vedotin plus bendamustine versus platinum-based regimens as 1st salvage therapy and 'bridge' to autologous hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma.
    Kaloyannidis P; Al Zayer M; Al Darweesh M; Al Batran M; Al Garni A; Al Naim A; Al Hashmi H; Kanfar S
    Leuk Lymphoma; 2023 Mar; 64(3):742-745. PubMed ID: 36628991
    [No Abstract]   [Full Text] [Related]  

  • 6. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.
    LaCasce AS; Bociek RG; Sawas A; Caimi P; Agura E; Matous J; Ansell SM; Crosswell HE; Islas-Ohlmayer M; Behler C; Cheung E; Forero-Torres A; Vose J; O'Connor OA; Josephson N; Wang Y; Advani R
    Blood; 2018 Jul; 132(1):40-48. PubMed ID: 29703778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The addition of bendamustine to brentuximab vedotin leads to improved rates of complete metabolic remission in children, adolescents and young adults with relapsed and refractory classical Hodgkin lymphoma: a retrospective single-centre series.
    McMillan A; O'Neill AT; Townsend W; Lambert J; Virchis A; Shah R; Menezes L; Humphries P; Von Both K; Grandage V; Carpenter B; Hough R; Ardeshna KM; Daw S
    Br J Haematol; 2021 Feb; 192(3):e84-e87. PubMed ID: 33426648
    [No Abstract]   [Full Text] [Related]  

  • 8. Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey.
    Salihoglu A; Elverdi T; Karadogan I; Paydas S; Ozdemir E; Erdem G; Karadurmus N; Akyol G; Kaynar L; Yegin Z; Sucak G; Ozkocaman V; Topcuoglu P; Ozcan M; Birtas E; Goker H; Baslar Z; Ferhanoglu B
    Ann Hematol; 2015 Mar; 94(3):415-20. PubMed ID: 25231929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma.
    LaCasce AS; Bociek RG; Sawas A; Caimi P; Agura E; Matous J; Ansell SM; Crosswell HE; Islas-Ohlmayer M; Behler C; Cheung E; Forero-Torres A; Vose J; O'Connor OA; Josephson N; Wang Y; Advani R
    Br J Haematol; 2020 May; 189(3):e86-e90. PubMed ID: 32048731
    [No Abstract]   [Full Text] [Related]  

  • 10. Brentuximab Vedotin in Combination With Dacarbazine or Bendamustine for Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Multi-Cohort Phase 2 Study.
    Clin Adv Hematol Oncol; 2016 Feb; 14(2 Suppl 1):13-5. PubMed ID: 27007006
    [No Abstract]   [Full Text] [Related]  

  • 11. Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin.
    Zinzani PL; Derenzini E; Pellegrini C; Celli M; Broccoli A; Argnani L
    Br J Haematol; 2013 Dec; 163(5):681-3. PubMed ID: 24032977
    [No Abstract]   [Full Text] [Related]  

  • 12. Retreatment with brentuximab vedotin in patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: a multicenter retrospective study.
    Fukuhara N; Yamamoto G; Tsujimura H; Chou T; Shibayama H; Yanai T; Shibuya K; Izutsu K
    Leuk Lymphoma; 2020 Jan; 61(1):176-180. PubMed ID: 31437057
    [No Abstract]   [Full Text] [Related]  

  • 13. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma.
    Chen R; Gopal AK; Smith SE; Ansell SM; Rosenblatt JD; Savage KJ; Connors JM; Engert A; Larsen EK; Huebner D; Fong A; Younes A
    Blood; 2016 Sep; 128(12):1562-6. PubMed ID: 27432875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis.
    Plattel WJ; Bergamasco A; Trinchese F; Gavini F; Bent-Ennakhil N; Zomas A; Castillon G; Arredondo-Bisono T; Cristarella T; Moride Y; von Tresckow B
    Leuk Lymphoma; 2021 Dec; 62(14):3320-3332. PubMed ID: 34323643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase II study of FIL ONLUS.
    Stefoni V; Marangon M; Re A; Lleshi A; Bonfichi M; Pinto A; Bianchetti N; Pellegrini C; Argnani L; Zinzani PL
    Haematologica; 2020 Oct; 105(10):e512. PubMed ID: 33054094
    [No Abstract]   [Full Text] [Related]  

  • 16. Brentuximab vedotin followed by bendamustine supercharge for refractory or relapsed Hodgkin lymphoma.
    Picardi M; Della Pepa R; Giordano C; Pugliese N; Mortaruolo C; Trastulli F; Rascato MG; Cappuccio I; Raimondo M; Memoli M; Monteverde M; Mascolo M; Pane F
    Blood Adv; 2019 May; 3(9):1546-1552. PubMed ID: 31088808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience.
    Rothe A; Sasse S; Goergen H; Eichenauer DA; Lohri A; Jäger U; Bangard C; Böll B; von Bergwelt Baildon M; Theurich S; Borchmann P; Engert A
    Blood; 2012 Aug; 120(7):1470-2. PubMed ID: 22786877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bendamustine can be a bridge to allogeneic transplantation in relapsed Hodgkin lymphoma refractory to brentuximab vedotin.
    Howell M; Gibb A; Radford J; Linton K
    Br J Haematol; 2017 Dec; 179(5):841-843. PubMed ID: 27447404
    [No Abstract]   [Full Text] [Related]  

  • 19. Brentuximab vedotin in association with bendamustine in refractory or multiple relapsed Hodgkin lymphoma. A retrospective real-world study.
    Iannitto E; Romano A; Scalzulli PR; Bonanno V; Scalone R; Chiarenza A; Pirosa MC; Caruso AL; Minoia C; Mantuano S; De Santis G; Salerno M; Crescimanno A; Porretto F; Li Gioi F; Ricciuti G; Greco A; Pavone E; Guarini A; Tarantini G; Mannina D; Consoli U; Cascavilla N; Di Raimondo F; Musso M
    Eur J Haematol; 2020 Jun; 104(6):581-587. PubMed ID: 32107795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comment on "Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study.".
    Picardi M; Giordano C
    Haematologica; 2021 Apr; 106(4):1226-1227. PubMed ID: 33792226
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.